Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - hepatitis a virus (inactivated) - injection - 25 u/0.5 ml - hepatitis a virus (inactivated) 25 u/0.5 ml

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - poliovirus type 1 antigen (formaldehyde inactivated) (unii: 0lvy784c09) (poliovirus type 1 antigen (formaldehyde inactivated) - unii:0lvy784c09), poliovirus type 2 antigen (formaldehyde inactivated) (unii: 23je9kdf4r) (poliovirus type 2 antigen (formaldehyde inactivated) - unii:23je9kdf4r), poliovirus type 3 antigen (formaldehyde inactivated) (unii: 459rom8m9m) (poliovirus type 3 antigen (formaldehyde inactivated) - unii:459rom8m9m) - poliovirus type 1 antigen (formaldehyde inactivated) 40 [d'ag'u] in 0.5 ml - ipol vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. (28) it is recommended that all infants (as young as 6 weeks of age), unimmunized children, and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis. (29) following the eradication of poliomyelitis caused by wild poliovirus from the western hemisphere (including north and south america) (30), an ipv-only schedule was recommended to eliminate vapp. (7) all children should receive four doses of ipv at ages 2, 4, 6 to 18 months, and 4 to 6 years. opv is no longer available in the us and is not recommended for routine immunization. (7) previous clinical poliomyelitis (usually due to only a single poliovirus type) or incomplete immunization with opv are not contraindications to completing the primary series of immunization with ipol vaccine. children of all ages should have their immuni

United States - English - NLM (National Library of Medicine)

gsk vaccines gmbh - rabies virus strain flury lep antigen (propiolactone inactivated) (unii: fk894q51ye) (rabies virus strain flury lep antigen (propiolactone inactivated) - unii:fk894q51ye) - rabies virus strain flury lep antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - rabavert is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups. usually, an immunization series is initiated and completed with one vaccine product. no clinical studies have been conducted that document a change in efficacy or the frequency of adverse reactions when the series is completed with a second vaccine product. however, for booster immunization, rabavert was shown to elicit protective antibody level responses in persons tested who received a primary series with hdcv (4,11). (see also dosage and administration section below) preexposure vaccination consists of three doses of rabavert 1.0 ml, intramuscularly (deltoid region), one each on days 0, 7, and 21 or 28 (1) (see also table 1 for criteria for preexposure vaccination). preexposure vaccination does not eliminate the need for additional therapy after a known rabies exposure (see also dosage and administration section, subsection c). preexposure vaccina

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis a virus antigen, quantity: 1440 elisa unit - injection, suspension - excipient ingredients: polysorbate 20; dibasic sodium phosphate heptahydrate; monobasic potassium phosphate; sodium chloride; potassium chloride; water for injections; aluminium hydroxide hydrate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - havrix is indicated for active immunisation against hepatitis a virus (hav) infection in susceptible subjects at risk of exposure to hav. havrix junior is indicated in subjects aged 2 to 15 years and havrix 1440 is indicated in subjects aged 16 years and older. in areas of low prevalence of hepatitis a, immunisation with havrix is particularly recommended in the following subjects: travellers : persons travelling to areas of intermediate or high endemicity for hepatitis a. these areas include africa, asia, india, the pacific islands, the mediterranean basin, the middle east, central and south america. armed forces : armed forces personnel who travel to higher endemicity areas or to areas where hygiene is poor, have an increased risk of hav infection. persons for whom hepatitis a is an occupational hazard or for whom there is an increased risk of transmission. these include: employees in day-care centres particularly in situations where children have not been toilet trained; teachers and other close contacts o

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - leptospira interrogans serovar hardjo; leptospira interrogans serovar pomona; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; thiomersal - parenteral liquid/solution/suspension - leptospira interrogans serovar hardjo vaccine-microbial active 0.0 p; leptospira interrogans serovar pomona vaccine-microbial active 0.0 p; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.15 mg/ml - immunotherapy - calf | cattle - beef | dairy cattle | beef calf | bovine | breeders | bullocks | bulls | calf - poddy | calf - preweaning | calf - vaccine | equine rotavirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - bordetella bronchiseptica; canine parainfluenza virus; aluminium hydroxide - misc. vaccines or anti sera - bordetella bronchiseptica vaccine-microbial active 0.05 ug/ml; canine parainfluenza virus vaccine-viral active 1000000.0 tci50/ml; aluminium hydroxide mineral-aluminium-base other 3.0 mg/ml - immunotherapy - dog - with exclusions see label - bordetella spp. | canine parainfluenza | bordetella bronchiseptica

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - infectious bovine rhinotracheitis virus strain int 1 pi3 virus (strain int 2) - pdr and diluent for intra-nasal soln - bovine - immunological - live vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - infectious bovine rhinotracheitis strain ts rlb 106 parainfluenza type 3 strain ts rlb 103 - pdr and diluent for intra-nasal soln - bovine - immunological - live vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

elanco europe ltd - bovine viral diarrhoea (bvd) virus strain ky1203nc (inactivated): - suspension for injection - bovine viral diarrhea vaccine (bvd) - bovine - immunological - inactivated vaccine

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - bovine respiratory syncytial virus - powder and solvent for solution for injection - live viral vaccine - cattle